Splenic abscess in cancer chemotherapy

• Published in: BMC research notes Vol. 8; no. 664; p. 665
• Main Authors: Ismail, Essadi, El Barni, Rachid, Lahkim, Mohamed, Rokhsi, Redouane, Atmane, Elmehdi, El Fikri, Abdelghani, Bouchama, Rachid, Achour, Abdessamad, Zyani, Mohamed
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11-11-2015; BioMed Central
• Subjects: Abscess; Abscess - diagnosis; Abscess - drug therapy; Abscess - surgery; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Anti-Bacterial Agents - therapeutic use; Antimitotic agents; Antimitotic Agents - therapeutic use; Antineoplastic agents; Cancer; Care and treatment; Case Report; Chemotherapy; Combined Modality Therapy; Dosage and administration; Health aspects; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Mortality; Neoplasm Metastasis; Splenectomy; Splenic Diseases - diagnosis; Splenic Diseases - drug therapy; Splenic Diseases - surgery; Splenomegaly; Treatment Outcome
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-015-1655-1

Splenic abcess is an uncommon complication for cancer treatment. It occurs more frequently in immunocompromised patients. They are characterized by high mortality. The classic triad (fever, pain of the left hypochondrium, and sensitive mass left) is only present in one-third of cases the clinical spectrum ranging from no symptoms to events such as fever, nausea, vomiting, weight loss, abdominal pain left, splenomegaly. Treatment options are limited, but must be discussed and adapted to the patient profile.
We report the case of a 62-year-old Arabic male, diagnosed with metastatic lung adenocarcinoma, who, after several cycles of chemotherapy, presented symptoms and signs of splenic abcess.
Splenic abcess is rare situation, which must be actively researched, to have access to an optimal therapeutic approach.